ScinoPharm Taiwan Balance Sheet Health
Financial Health criteria checks 6/6
ScinoPharm Taiwan has a total shareholder equity of NT$10.4B and total debt of NT$35.7M, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are NT$11.8B and NT$1.3B respectively. ScinoPharm Taiwan's EBIT is NT$446.6M making its interest coverage ratio -8.8. It has cash and short-term investments of NT$4.0B.
Key information
0.3%
Debt to equity ratio
NT$35.70m
Debt
| Interest coverage ratio | -8.8x |
| Cash | NT$3.98b |
| Equity | NT$10.44b |
| Total liabilities | NT$1.34b |
| Total assets | NT$11.78b |
Recent financial health updates
Recent updates
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 17
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First
Apr 04A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Mar 14Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock
Feb 21ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares
Jan 25
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease
Jan 04Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Dec 14Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?
Nov 23Financial Position Analysis
Short Term Liabilities: 1789's short term assets (NT$6.5B) exceed its short term liabilities (NT$694.0M).
Long Term Liabilities: 1789's short term assets (NT$6.5B) exceed its long term liabilities (NT$650.4M).
Debt to Equity History and Analysis
Debt Level: 1789 has more cash than its total debt.
Reducing Debt: 1789's debt to equity ratio has reduced from 2.6% to 0.3% over the past 5 years.
Debt Coverage: 1789's debt is well covered by operating cash flow (1553.7%).
Interest Coverage: 1789 earns more interest than it pays, so coverage of interest payments is not a concern.